Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement negotiations. …
The Russian Intellectual Property Court (IPC) recently revoked an extension (SPC) of Pfizer's Eurasian patent No. 012666 relating to the composition of tofacitinib in relation to the Russian…
On 1 September 2025, Michael Tappin KC sitting as a Deputy Judge of the High Court handed down a judgment in favour of Bayer’s application to strike out Sandoz’s claim for an account of profits under…
Readers will likely be aware of the cross-jurisdictional litigation considering infringement by Samsung Bioepis / Amgen’s biosimilar eculizumab products of Alexion’s patent, EP 3 167 888 B1 (“EP 888”…
The final week of July usually produces a flurry, and sometimes an avalanche, of decisions from the English Courts as Judges attempt to clear their desks before the holiday period. This year was no…
Tempus fugit. It’s hard to believe that the UPC opened for business over two years ago and, after a relatively slow start, is now flourishing. It would be fair to say that, with certain notable…
In the UK, as well as in many other countries, being the first to market with a generic or biosimilar to a leading branded medicine is a critical strategy that can offer a major advantage to a…
On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…
On 30 October 2024, the District Court of the Hague handed down two merits decisions on the widely litigated apixaban patent of Bristol-Myers Squibb (see here and here - Dutch language versions). EP…
